查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2004923

核医放射性同位素市场：2026-2032年全球市场预测（依同位素功能、给药途径、生产技术、最终用户和疾病领域划分）

Nuclear Medicine Radioisotopes Market by Isotope Function, Mode Of Administration, Production Technology, End User, Disease Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核医放射性同位素市场价值将达到 68.9 亿美元，到 2026 年将成长至 75.5 亿美元，到 2032 年将达到 134.4 亿美元，复合年增长率为 9.99%。

主要市场统计数据
基准年 2025 68.9亿美元
预计年份：2026年 75.5亿美元
预测年份 2032 134.4亿美元
复合年增长率 (%) 9.99%

这是一本权威的入门书籍，说明了临床创新、生产技术和监管变化如何重塑核医放射性同位素生态系统。

核医学放射性同位素产业目前正经历重大变革时期，其驱动力来自临床创新、生产技术的转变以及监管重点的不断变化。该行业传统上专注于影像学以及发生器生产的少量同位素，如今已扩展到精准医疗、一体化诊疗路径以及分散式生产模式，这些都对传统的供应链提出了挑战。因此，医疗系统、製造商和监管相关人员都面临新的技术和商业性现实，需要采取明智且具有策略性的应对措施。

简要反思临床实践、生产方法和监管期望的系统性变革，这些变革正在重新定义该领域。

过去几年，核子医学领域放射性同位素的临床应用、供应链和法规结构都发生了变革性变化。在临床上，将诊断影像和标靶放射治疗紧密结合的「治疗诊断学」模式正迅速发展，改变标准的治疗路径，并催生了对特定放射性同位素和标记化合物的新需求模式。同时，分子标靶和放射化学领域的进展正在扩大多种药物的治疗指数，从而促进更广泛的临床评估和应用。

重点分析美国在 2025 年推出的关税措施如何重塑采购、供应链战略和区域製造业优先事项。

2025年，美国关税政策的变化进一步扰乱了依赖跨境供应放射性同位素前体、发生器、合成模组和专用耗材的相关人员。这种累积影响体现在筹资策略、供应链结构和成本结构的各个方面。依赖进口的企业被迫重新评估其供应商，许多企业正在加快本地製造计划或在未受关税调整影响的市场中寻找替代供应商。

详细的分割分析表明，诊断用 PET 和 SPECT 显像剂和治疗方式各自需要不同的技术、临床和商业性策略。

細項分析揭示了诊断和治疗性放射性药物在技术、临床和商业性的显着趋势。诊断性放射性药物分为PET和SPECT两大类。在PET放射性药物中，F-18 FDG已成为肿瘤学中常用的常规影像工具，而F-18 PSMA由于其优于其他PSMA示踪剂的特异性和易用性，在前列腺癌分期和復发检测中日益受到重视。 SPECT放射性药物在γ射线发射同位素仍然经济有效且广泛可用的领域继续发挥广泛的临床作用。治疗性放射性药物包括针对生长抑制素受体的同位素和配体依赖性胜肽受体放射性核素疗法（对神经内分泌肿瘤具有良好的剂量分布特性）、将高剂量β射线发射药物直接输送到肝臟肿瘤的放射性栓塞疗法，以及将单株抗体和细胞毒性同位素联合用于标靶全身性治疗的放射免疫疗法。

主要区域展望显示美洲、欧洲、中东和非洲以及亚太地区在采用率、製造能力和法规环境的差异。

区域差异导緻美洲、欧洲、中东和非洲以及亚太地区在PET示踪剂的应用曲线、监管方式和製造地存在显着差异。在美洲，一体化的医疗网路和先进的影像基础设施支援新型PET示踪剂和诊疗一体化製剂的快速临床应用，同时相关政策和报销框架也在不断发展，以适应高价值放射疗法的需求。相较之下，欧洲、中东和非洲地区的情况则较为复杂，既有成熟的高效医疗中心，也有面临物流和监管障碍的地区。泛欧监管协调工作和各国为确保同位素供应而采取的措施正在影响製造商和临床机构的策略规划。

产业领导者正在实施策略性企业应对措施和伙伴关係模式，以确保供应链安全、加速临床部署并透过自身能力实现差异化。

放射性同位素领域的企业策略如今强调整合价值链、策略伙伴关係和能力主导的差异化。各公司优先投资迴旋加速器网路和自动化合成平台等生产技术，同时拓展其放射化学和临床开发能力。随着各公司致力于降低供应风险、缩短临床试验週期并累积证据以支持医保报销和更广泛的临床应用，同位素生产商、合约研发生产机构 (CDMO) 和临床服务提供者之间的合作日益普遍。

产业领导者可以实施的可操作建议，以加强供应链韧性、加速临床检验并有效实现治疗诊断学创新商业化。

产业领导者应推动一系列合作倡议，以增强供应链韧性，加速临床检验，并建构一个能够从新兴的治疗诊断学模式中获取长期价值的系统。首先，应优先投资区域生产能力和检验的替代生产路线，以减少对单一来源进口的依赖。其次，应促进放射化学家、医学物理学家和临床试验负责人之间的跨学科合作，以产生可靠的临床证据，并完善剂量和安全通讯协定，从而改善患者疗效并增强支付方的信心。

采用严谨的混合方法研究途径，结合专家的初步访谈、技术文献的整合以及製造和监管流程的梳理。

本分析所依据的研究采用了一种混合方法，旨在整合技术、临床和商业性观点。研究人员透过对临床医生、放射药剂师、生产专家和监管顾问进行结构化访谈，收集了主要的定性数据，以了解实际操作情况、未满足的需求以及推广应用的障碍。这些发现与二手技术文献、同行评审的临床研究、监管指导文件以及公开的临床试验註册资讯进行了交叉比对，从而全面了解了科学和临床趋势。

一项决定性的整合，突显了临床创新、製造现代化和协作策略之间为未来成功而进行的关键相互作用。

总之，核医放射性同位素正处于临床创新、生产现代化和监管完善的快速发展交会点。治疗诊断学的兴起、迴旋加速器能力的提升以及对更具韧性的供应链的需求，正在改变放射性药物的研发、生产和交付方式。医疗系统和生产商若能将自身的技术能力与临床项目的设计以及积极的监管互动相结合，将更有利于把科学进步转化为更优质的患者照护。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核子医学放射性同位素市场－依同位素功能划分

  • 诊断同位素
    • 用于SPECT的同位素
      • Technetium-99m (Tc-99m)
      • 碘-123 (I-123)
      • 铊-201 (Tl-201)
      • 镓-67（Ga-67）
      • 铟-111 (In-111)
    • 用于PET的同位素
      • 氟-18 (F-18)
      • 碳-11 (C-11)
      • 氮-13 (N-13)
      • 氧-15（O-15）
      • 铷-82 (Rb-82)
      • 铜-64 (Cu-64)
  • 治疗性同位素
    • β射线放射体
    • α粒子发射材料
    • 俄歇电子发射器
    • 用于近距离治疗的同位素

第九章：依给药方式分類的核医学放射性同位素市场分布

  • 静脉注射
  • 口服

第十章 核医放射性同位素市场（依生产技术划分）

  • 由核子反应炉製造
  • 采用迴旋加速器法製造
  • 发电机
  • 利用直线加速器进行製造

第十一章：核医放射性同位素市场：依最终用户划分

  • 学术和研究机构
  • 诊断影像中心
  • 医院
  • 製药和生物技术公司

第十二章 按疾病领域分類的核子医学放射性同位素市场

  • 肿瘤学
  • 循环系统
  • 神经病学
  • 内分泌学
  • 肺科
  • 肾臟病学
  • 胃肠病学
  • 感染疾病和炎症

第十三章：核医放射性同位素市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：核医放射性同位素市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：核医放射性同位素市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国核子医学放射性同位素市场

第十七章 中国核医放射性同位素市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BWX Technologies Inc
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Curium Pharma
  • Eckert & Ziegler AG
  • GE HealthCare Technologies Inc
  • Ionetix Corporation
  • IRE ELiT
  • ISOFLEX USA
  • ITM Isotope Technologies Munich SE
  • Life Molecular Imaging
  • NECSA Ltd
  • NorthStar Medical Radioisotopes LLC
  • NTP Radioisotopes SOC Ltd
  • Nusano
  • Orano Med
  • SOFIE Biosciences Inc
  • Telix Pharmaceuticals Ltd
Product Code: MRR-742BD51821D7

The Nuclear Medicine Radioisotopes Market was valued at USD 6.89 billion in 2025 and is projected to grow to USD 7.55 billion in 2026, with a CAGR of 9.99%, reaching USD 13.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.89 billion
Estimated Year [2026] USD 7.55 billion
Forecast Year [2032] USD 13.44 billion
CAGR (%) 9.99%

An authoritative introduction explaining how clinical innovation, production technology, and regulatory shifts are reshaping nuclear medicine radioisotope ecosystems

The landscape of nuclear medicine radioisotopes is undergoing a period of substantive change driven by converging clinical innovations, shifts in production technology, and evolving regulatory priorities. Historically centered on diagnostic imaging and a small set of generator-produced isotopes, the field now spans precision therapeutics, integrated diagnostic-therapeutic pathways, and more distributed production models that challenge legacy supply chains. As a result, stakeholders across healthcare systems, manufacturers, and regulators are confronting new technical and commercial realities that require informed strategic responses.

In clinical settings, the expansion of theranostics and targeted radionuclide therapies has redefined disease management for oncology and other specialties, increasing demand for reliable isotopic supply, specialized radiochemistry capabilities, and robust logistics. Concurrently, manufacturing innovations such as expanded cyclotron deployment and alternative Mo-99/Tc-99m production pathways are emerging to mitigate historical bottlenecks. Taken together, these forces are reshaping investment priorities and partnership structures. Therefore, an introduction to this domain must emphasize both the technical specifics of isotope production and the system-level implications for clinical adoption, reimbursement, and cross-industry collaboration.

A concise examination of the systemic transformations in clinical practice, production methods, and regulatory expectations that are redefining the sector

The past several years have revealed transformative shifts that are redefining the nuclear medicine radioisotopes landscape across clinical practice, supply chains, and regulatory frameworks. Clinically, the rapid uptake of theranostic paradigms-where diagnostic imaging tightly couples with targeted radiotherapeutics-has changed standard care pathways and created new demand profiles for specific radioisotopes and labeled compounds. Concurrent advances in molecular targeting and radiochemistry have expanded the therapeutic index for several agents, prompting broader clinical evaluation and adoption.

On the production side, there has been a marked move toward decentralization with greater investment in hospital-based and regional cyclotron capacity, as well as interest in alternative generator and reactor-independent production techniques. These developments are complemented by improvements in automation for synthesis and quality control, which streamline operations and reduce exposure risks. From a regulatory perspective, agencies are refining guidance to accommodate novel radiopharmaceutical manufacturing controls, aseptic processing innovations, and accelerated clinical pathways for high-need indications. Together, these shifts are creating a more resilient yet complex ecosystem that rewards integrated technical capability and agile regulatory engagement.

A focused analysis of how United States tariff measures introduced in 2025 are reshaping procurement, supply chain strategy, and regional manufacturing priorities

In 2025, tariff policy changes instituted by the United States introduced another vector of disruption for stakeholders who depend on cross-border supply of radioisotope precursors, generators, synthesis modules, and specialized consumables. The cumulative impacts are observable across procurement strategies, supply chain architecture, and cost structures. Import-dependent organizations have been prompted to reassess sourcing, with many accelerating local manufacturing projects or seeking alternative suppliers in markets unaffected by tariff adjustments.

Beyond procurement, tariffs have influenced contractual negotiations, inventory management practices, and long-term capital planning. Firms that previously relied on low-cost foreign components are now evaluating vertical integration or strategic partnerships to internalize critical capabilities. At the same time, regulatory and customs complexities have created operational friction that can extend lead times for clinical programs and manufacturing scale-up. As a consequence, industry players are prioritizing supply chain mapping, supplier qualification diversification, and investment in regionalized capacity to mitigate tariff-driven exposure and preserve continuity of care.

Granular segmentation insights revealing how diagnostic PET and SPECT agents and therapeutic modalities each demand distinct technical, clinical, and commercial strategies

Segmentation analysis reveals distinct technical, clinical, and commercial dynamics across diagnostic and therapeutic radiopharmaceuticals. Diagnostic agents split into PET and SPECT categories, with PET agents like F-18 FDG established as routine oncologic imaging tools and F-18 PSMA gaining prominence for prostate cancer staging and recurrence detection because of its superior specificity and logistical handling compared with some alternative PSMA tracers. SPECT agents continue to serve widespread clinical roles where gamma-emitting isotopes remain cost-effective and widely available. Therapeutic agents encompass peptide receptor radionuclide therapy, which leverages somatostatin receptor targeting for neuroendocrine tumors and depends on isotopes and ligands with favorable dosimetry profiles; radioembolization approaches that deliver high-dose beta emitters directly to hepatic tumors; and radioimmunotherapy strategies that combine monoclonal antibodies with cytotoxic isotopes for targeted systemic treatment.

These distinctions carry operational implications for manufacturers and providers. PET workflows require robust radiochemistry, rapid distribution, and regulatory compliance for short-lived isotopes, while therapeutic modalities demand specialized dosimetry, patient selection protocols, and multidisciplinary clinical teams. Consequently, organizations involved in radiopharmaceutical development must align laboratory capabilities, distribution networks, and clinical partnerships to address the unique requirements of each segment and to translate scientific advances into meaningful patient outcomes.

Key regional perspectives showing how adoption, manufacturing capacity, and regulatory environments vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geographic variation drives meaningful differences in adoption curves, regulatory approaches, and manufacturing footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated healthcare networks and advanced imaging infrastructure support rapid clinical adoption of novel PET tracers and theranostic agents, while policy and reimbursement frameworks are evolving to accommodate high-value radiotherapeutics. By contrast, Europe, the Middle East & Africa present a heterogeneous landscape where well-established centers of excellence coexist with regions that face logistical and regulatory hurdles; pan-European regulatory harmonization efforts and national initiatives to secure isotope supply influence strategic planning for producers and clinical sites.

In the Asia-Pacific region, rapid investment in cyclotron capacity, growing clinical trial activity, and increasing domestic manufacturing capabilities are notable trends. Several markets in the region are focusing on expanding local production to reduce import dependency and to address rising clinical demand. Across all regions, differences in reimbursement models, hospital infrastructure, and regulatory timelines necessitate tailored commercialization strategies and local partnerships to achieve sustainable access and scale.

Strategic corporate responses and partnership models that industry leaders are deploying to secure supply chains, accelerate clinical adoption, and differentiate through capabilities

Corporate strategies in the radioisotope domain now emphasize integrated value chains, strategic partnerships, and capability-led differentiation. Firms are prioritizing investments in production technologies, such as cyclotron networks and automated synthesis platforms, while also expanding capabilities in radiochemistry and clinical development. Collaboration between isotope producers, contract development and manufacturing organizations, and clinical providers is increasingly prevalent as organizations seek to de-risk supply, accelerate time to clinic, and build evidence that supports reimbursement and broader clinical adoption.

In addition, companies are diversifying route-to-market approaches by licensing proprietary ligands, forming co-development agreements for theranostic pairs, and pursuing regional manufacturing alliances. Intellectual property management, quality systems harmonization, and regulatory engagement remain central to competitive positioning. Collectively, these strategies reflect a shift from single-product development toward end-to-end solutions that marry isotope supply security with clinical utility and commercial scalability.

Actionable recommendations that industry leaders can implement to strengthen supply resilience, accelerate clinical validation, and commercialize theranostic innovations effectively

Industry leaders should pursue a coordinated set of actions that strengthen supply resilience, accelerate clinical validation, and position organizations to capture long-term value from emerging theranostic paradigms. First, prioritize investment in regional production capacity and validated alternative production pathways to reduce dependency on single-source imports. Second, cultivate multidisciplinary collaborations between radiochemists, medical physicists, and clinical trialists to generate robust clinical evidence and to refine dosing and safety protocols that improve patient outcomes and payer confidence.

Furthermore, organizations should engage proactively with regulators to shape pragmatic pathways for quality assurance, sterility testing, and lot release that reflect the technical realities of short-lived isotopes. Operationally, integrating automation and digital quality controls can reduce turnaround times and enhance reproducibility. Finally, commercial strategies must focus on building payer relationships and demonstrating real-world value through outcomes and health economic evidence, while also developing flexible distribution and inventory models that accommodate the logistical constraints of radiopharmaceuticals.

A rigorous mixed-methods research approach integrating primary expert interviews, technical literature synthesis, and production and regulatory process mapping

The research underpinning this analysis employed a mixed-methods approach designed to integrate technical, clinical, and commercial perspectives. Primary qualitative data were collected through structured interviews with clinicians, radiopharmacists, manufacturing specialists, and regulatory advisors to capture operational realities, unmet needs, and adoption barriers. These insights were triangulated with secondary technical literature, peer-reviewed clinical studies, regulatory guidance documents, and publicly available clinical trial registries to ensure a comprehensive understanding of scientific and clinical trends.

Analytical steps included a systematic mapping of production technologies, a review of manufacturing process controls relevant to radiopharmaceuticals, and an assessment of logistics and cold-chain considerations specific to short-lived isotopes. The methodology emphasized reproducibility by documenting data sources, interview protocols, and analytical assumptions, and by conducting sensitivity checks on qualitative findings. Where applicable, patent landscapes and regulatory filings were examined to validate strategic positioning and to identify potential technology inflection points.

A conclusive synthesis emphasizing the critical interplay of clinical innovation, production modernization, and collaborative strategies for future success

In summary, nuclear medicine radioisotopes occupy a fast-evolving junction of clinical innovation, manufacturing modernization, and regulatory refinement. The rise of theranostics, expansion of cyclotron capacity, and the need for more resilient supply chains are collectively altering how radiopharmaceuticals are developed, produced, and delivered. Healthcare systems and manufacturers that align technical capabilities with clinical program design and proactive regulatory engagement will be best positioned to translate scientific advances into improved patient care.

Moving forward, success will depend on cross-sector collaboration, transparent supply chain strategies, and evidence generation that demonstrates clinical and economic value. By embracing integrated approaches that combine secure isotope production, automated manufacturing processes, and targeted clinical development, stakeholders can mitigate operational risk while accelerating adoption of next-generation diagnostic and therapeutic radiopharmaceuticals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Radioisotopes Market, by Isotope Function

  • 8.1. Diagnostic Isotopes
    • 8.1.1. SPECT Isotopes
      • 8.1.1.1. Technetium-99m (Tc-99m)
      • 8.1.1.2. Iodine-123 (I-123)
      • 8.1.1.3. Thallium-201 (Tl-201)
      • 8.1.1.4. Gallium-67 (Ga-67)
      • 8.1.1.5. Indium-111 (In-111)
    • 8.1.2. PET Isotopes
      • 8.1.2.1. Fluorine-18 (F-18)
      • 8.1.2.2. Carbon-11 (C-11)
      • 8.1.2.3. Nitrogen-13 (N-13)
      • 8.1.2.4. Oxygen-15 (O-15)
      • 8.1.2.5. Rubidium-82 (Rb-82)
      • 8.1.2.6. Copper-64 (Cu-64)
  • 8.2. Therapeutic Isotopes
    • 8.2.1. Beta Emitters
    • 8.2.2. Alpha Emitters
    • 8.2.3. Auger Electron Emitters
    • 8.2.4. Brachytherapy Isotopes

9. Nuclear Medicine Radioisotopes Market, by Mode Of Administration

  • 9.1. Intravenous Injection
  • 9.2. Oral Ingestion

10. Nuclear Medicine Radioisotopes Market, by Production Technology

  • 10.1. Nuclear Reactor Production
  • 10.2. Cyclotron Production
  • 10.3. Generator Systems
  • 10.4. Linear Accelerator Production

11. Nuclear Medicine Radioisotopes Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Nuclear Medicine Radioisotopes Market, by Disease Area

  • 12.1. Oncology
  • 12.2. Cardiology
  • 12.3. Neurology
  • 12.4. Endocrinology
  • 12.5. Pulmonology
  • 12.6. Nephrology
  • 12.7. Gastroenterology
  • 12.8. Infection And Inflammation

13. Nuclear Medicine Radioisotopes Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine Radioisotopes Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine Radioisotopes Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine Radioisotopes Market

17. China Nuclear Medicine Radioisotopes Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BWX Technologies Inc
  • 18.6. Cardinal Health
  • 18.7. China Isotope & Radiation Corporation
  • 18.8. Curium Pharma
  • 18.9. Eckert & Ziegler AG
  • 18.10. GE HealthCare Technologies Inc
  • 18.11. Ionetix Corporation
  • 18.12. IRE ELiT
  • 18.13. ISOFLEX USA
  • 18.14. ITM Isotope Technologies Munich SE
  • 18.15. Life Molecular Imaging
  • 18.16. NECSA Ltd
  • 18.17. NorthStar Medical Radioisotopes LLC
  • 18.18. NTP Radioisotopes SOC Ltd
  • 18.19. Nusano
  • 18.20. Orano Med
  • 18.21. SOFIE Biosciences Inc
  • 18.22. Telix Pharmaceuticals Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 254. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)